MD News and Information

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis

Author: Rucsandra Dobrota, Britta Maurer1, Nicole Graf, Suzana Jordan, Carina Mihai, Otylia Kowal-Bielecka, Yannick Allanore, Oliver Distler
Date Published: March-2016
Source: Annals of the Rheumatic Diseases

Improvement of skin fibrosis is part of the natural course of diffuse cutaneous systemic sclerosis (dcSSc). Recognising those patients most likely to improve could help tailoring clinical management and cohort enrichment for clinical trials. In this study, we aimed to identify predictors for improvement of skin fibrosis in patients with dcSSc.

 

Muscle Weakness Predicts Disability in Scleroderma

Author: Wayne Kuznar
Date Published: March-2016
Source: MedPage Today

Muscle weakness was independently associated with disability in patients with scleroderma, and as muscle weakness worsened, disability also increased, according to findings from a retrospective, nested, case control study. Patients with muscle weakness had an average Health Assessment Questionnaire-Disability Index (HAQ-DI) of 1.4, which indicates moderate to severe disability, according to Julie J. Paik, MD, MHS, and colleagues from Johns Hopkins University in Baltimore.

 

Actelion Stresses Importance of PAH Early Detection, Life Quality at 2016 SSc World Congress and in Exclusive Interview

Author: Patricia Silva
Date Published: February-2016
Source: Scleroderma News

New data was recently presented regarding Actelion Pharmaceuticals’ therapies and strategies to improve clinical outcomes in patients with pulmonary arterial hypertension (PAH). The data were presented at the Actelion Satellite Symposium, titled “Improving outcome in pulmonary arterial hypertension,” which was part of the 4th Systemic Sclerosis World Congress held in Lisbon, Portugal, on Feb. 18-20, 2016.

 

Systemic Sclerosis Mouse Study of Nintedanib in Fibrotic and Vascular Manifestations Looks Promising

Author: Daniela Semedo
Date Published: February-2016
Source: Scleroderma News

Nintedanib (OFEV) seems to inhibit the activation of fibroblasts and to exert an anti-fibrotic effect in mouse models of systemic sclerosis (SSc), according to data recently presented at the 4th Systemic Sclerosis World Congress in Lisbon, Portugal, last week. The presentation, “Effects of Nintedanib on Fibrotic and Vascular Manifestation in Pre-clinical Models of Systemic Sclerosis,” was given by J. Distler from the Department of International Medicine 3 and the Institute for Clinical Immunology at the University of Erlangen-Nuremberg in Germany.

 

Typical Therapies Not Tough Enough to Curb Digital Ulcers

Author: Damian McNamara
Date Published: February-2016
Source: Medscape

Patients with systemic sclerosis and a recent history of digital ulcers remain at significantly higher risk of developing a new one, according to an observational study. The findings also suggest a common treatment might be insufficient for prevention in this high-risk subset. The study is one of five observational studies that make up the DeSScipher project, sponsored by the Scleroderma Society in London, United Kingdom.

 

PAH Drug, Opsumit, Seen to Prevent and Treat Lung Disease in a Mouse Model of Scleroderma

Author: Margarida Azevedor
Date Published: February-2016
Source: Pulmonary Hypertension News

Researchers at University College London (UCL) and Actelion Pharmaceuticals presented a study investigating the therapeutic effect of macitentan (Opsumit) in a mouse model of pulmonary hypertension associated with systemic scleroderma (SSc). The presentation, titled “Macitentan Responsiveness Supports the Validity of a Murine Model of Pulmonary Hypertension in Scleroderma Associated with altered TGFbeta/BMPRII Signalling,” took place at the recent 4th Systemic Sclerosis World Congress in Lisbon, Portugal.

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 9 of 21